Cyclin‐dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus

These findings suggest that CDK activity may be a useful target in the treatment of systemic lupus erythematosus. A direct immunomodulatory action of seliciclib on T cells and B cells may be one of the mechanisms underlying the beneficial effects.